| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Warfarin | 20 | 2023 | 59 | 7.270 |
Why?
|
| Anticoagulants | 18 | 2023 | 97 | 4.750 |
Why?
|
| Pharmacogenetics | 18 | 2023 | 45 | 3.910 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2021 | 60 | 3.540 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 10 | 2023 | 49 | 3.230 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2023 | 638 | 2.170 |
Why?
|
| Genotype | 18 | 2023 | 641 | 1.910 |
Why?
|
| Ticlopidine | 4 | 2018 | 15 | 1.890 |
Why?
|
| Mixed Function Oxygenases | 6 | 2012 | 29 | 1.420 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 628 | 1.270 |
Why?
|
| Thrombosis | 3 | 2018 | 61 | 1.260 |
Why?
|
| Blood Platelets | 2 | 2018 | 74 | 1.200 |
Why?
|
| Polymorphism, Genetic | 5 | 2021 | 165 | 1.120 |
Why?
|
| Humans | 68 | 2023 | 34853 | 1.090 |
Why?
|
| Antibodies, Monoclonal | 9 | 2008 | 282 | 1.080 |
Why?
|
| Ascorbic Acid | 4 | 2012 | 63 | 1.030 |
Why?
|
| Diabetic Neuropathies | 2 | 2017 | 11 | 1.020 |
Why?
|
| Algorithms | 6 | 2020 | 435 | 0.940 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2019 | 13 | 0.920 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 35 | 0.910 |
Why?
|
| Aryldialkylphosphatase | 3 | 2018 | 9 | 0.870 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 14 | 0.830 |
Why?
|
| Mutation, Missense | 2 | 2018 | 80 | 0.790 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2017 | 592 | 0.680 |
Why?
|
| Aged | 13 | 2021 | 6448 | 0.680 |
Why?
|
| Puerto Rico | 10 | 2021 | 1352 | 0.680 |
Why?
|
| Metformin | 2 | 2017 | 64 | 0.650 |
Why?
|
| Male | 25 | 2021 | 18870 | 0.650 |
Why?
|
| Tetrazoles | 1 | 2018 | 49 | 0.630 |
Why?
|
| Stents | 2 | 2018 | 59 | 0.630 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 984 | 0.620 |
Why?
|
| Drug Resistance | 1 | 2017 | 93 | 0.590 |
Why?
|
| Carotid Artery Diseases | 1 | 2017 | 22 | 0.590 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 37 | 0.580 |
Why?
|
| Gene Frequency | 6 | 2020 | 155 | 0.580 |
Why?
|
| Drug Combinations | 1 | 2015 | 89 | 0.540 |
Why?
|
| Female | 23 | 2021 | 19873 | 0.540 |
Why?
|
| Drug Interactions | 1 | 2015 | 137 | 0.530 |
Why?
|
| Neoplasms | 4 | 2022 | 1033 | 0.520 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2016 | 17 | 0.520 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 209 | 0.520 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 105 | 0.500 |
Why?
|
| Hemorrhage | 1 | 2014 | 46 | 0.500 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 74 | 0.480 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 2333 | 0.440 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 102 | 0.440 |
Why?
|
| Vitamins | 3 | 2015 | 91 | 0.430 |
Why?
|
| Middle Aged | 11 | 2021 | 9642 | 0.420 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 52 | 0.410 |
Why?
|
| Metabolic Clearance Rate | 2 | 2008 | 22 | 0.400 |
Why?
|
| Dietary Supplements | 2 | 2015 | 196 | 0.390 |
Why?
|
| Treatment Outcome | 4 | 2020 | 1349 | 0.390 |
Why?
|
| Caribbean Region | 3 | 2020 | 63 | 0.370 |
Why?
|
| Metagenomics | 1 | 2009 | 32 | 0.340 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2005 | 38 | 0.340 |
Why?
|
| Problem-Based Learning | 1 | 2008 | 32 | 0.330 |
Why?
|
| Education, Pharmacy | 1 | 2008 | 32 | 0.330 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 7 | 0.320 |
Why?
|
| Clinical Competence | 1 | 2008 | 124 | 0.310 |
Why?
|
| Heart Failure | 1 | 2010 | 230 | 0.310 |
Why?
|
| Retrospective Studies | 4 | 2019 | 1961 | 0.310 |
Why?
|
| Epidermal Growth Factor | 2 | 2004 | 63 | 0.300 |
Why?
|
| Enzymes | 3 | 2015 | 30 | 0.290 |
Why?
|
| Half-Life | 4 | 2016 | 52 | 0.290 |
Why?
|
| Risk Factors | 5 | 2017 | 3414 | 0.290 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 2561 | 0.290 |
Why?
|
| Micronutrients | 3 | 2015 | 42 | 0.290 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2015 | 82 | 0.280 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 195 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2004 | 242 | 0.260 |
Why?
|
| Biological Products | 1 | 2006 | 67 | 0.260 |
Why?
|
| Area Under Curve | 6 | 2007 | 91 | 0.250 |
Why?
|
| Mice, Nude | 7 | 2015 | 323 | 0.250 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 22 | 0.240 |
Why?
|
| Cohort Studies | 3 | 2020 | 1422 | 0.230 |
Why?
|
| Prospective Studies | 2 | 2020 | 1353 | 0.230 |
Why?
|
| Alleles | 3 | 2021 | 284 | 0.210 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 271 | 0.210 |
Why?
|
| West Indies | 1 | 2021 | 10 | 0.210 |
Why?
|
| Buprenorphine | 1 | 2021 | 19 | 0.210 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2021 | 23 | 0.210 |
Why?
|
| Injections, Intravenous | 3 | 2008 | 58 | 0.200 |
Why?
|
| Endocytosis | 1 | 2002 | 104 | 0.200 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2021 | 44 | 0.200 |
Why?
|
| United States | 6 | 2020 | 3894 | 0.200 |
Why?
|
| Adult | 8 | 2019 | 11034 | 0.200 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 570 | 0.200 |
Why?
|
| Thromboembolism | 1 | 2020 | 14 | 0.190 |
Why?
|
| Platelet Aggregation | 2 | 2018 | 17 | 0.190 |
Why?
|
| Dinucleoside Phosphates | 1 | 2020 | 11 | 0.190 |
Why?
|
| Apoptosis | 1 | 2008 | 1317 | 0.190 |
Why?
|
| Mice | 10 | 2021 | 5668 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 112 | 0.180 |
Why?
|
| Linear Models | 2 | 2017 | 253 | 0.180 |
Why?
|
| Geography | 1 | 2019 | 86 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 794 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 756 | 0.170 |
Why?
|
| Coenzymes | 2 | 2015 | 11 | 0.170 |
Why?
|
| Animals | 15 | 2021 | 14307 | 0.170 |
Why?
|
| Neonatal Screening | 1 | 2018 | 26 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2018 | 628 | 0.160 |
Why?
|
| Genetic Markers | 1 | 2018 | 118 | 0.160 |
Why?
|
| Heterozygote | 2 | 2015 | 91 | 0.160 |
Why?
|
| Budesonide | 1 | 2017 | 5 | 0.160 |
Why?
|
| Malnutrition | 2 | 2015 | 45 | 0.160 |
Why?
|
| Drug Synergism | 1 | 2018 | 171 | 0.160 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 217 | 0.160 |
Why?
|
| Particulate Matter | 1 | 2017 | 49 | 0.150 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 213 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2019 | 283 | 0.140 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 2 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 221 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 424 | 0.140 |
Why?
|
| Legislation, Drug | 1 | 2015 | 5 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 17 | 0.140 |
Why?
|
| Homozygote | 1 | 2015 | 75 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2017 | 517 | 0.140 |
Why?
|
| Demography | 1 | 2016 | 167 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2018 | 871 | 0.130 |
Why?
|
| Energy Metabolism | 2 | 2015 | 160 | 0.130 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2015 | 21 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2015 | 57 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 32 | 0.130 |
Why?
|
| Carbazoles | 1 | 2015 | 43 | 0.130 |
Why?
|
| Rabbits | 2 | 2005 | 278 | 0.130 |
Why?
|
| Logistic Models | 1 | 2017 | 894 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2017 | 727 | 0.120 |
Why?
|
| Phenotype | 1 | 2017 | 650 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2015 | 112 | 0.120 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 152 | 0.120 |
Why?
|
| Tissue Distribution | 6 | 2006 | 197 | 0.120 |
Why?
|
| Blood Glucose | 2 | 2015 | 333 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 446 | 0.120 |
Why?
|
| Prevalence | 3 | 2019 | 1425 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 207 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 173 | 0.120 |
Why?
|
| Time Factors | 2 | 2010 | 1681 | 0.110 |
Why?
|
| Models, Biological | 2 | 2015 | 642 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 406 | 0.110 |
Why?
|
| Drugs, Generic | 1 | 2012 | 4 | 0.110 |
Why?
|
| Prescription Drugs | 1 | 2012 | 31 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 371 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2012 | 429 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 485 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 10 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 187 | 0.100 |
Why?
|
| Haplotypes | 2 | 2021 | 152 | 0.090 |
Why?
|
| Technetium | 2 | 1999 | 11 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2000 | 55 | 0.090 |
Why?
|
| Disease Progression | 1 | 2011 | 580 | 0.090 |
Why?
|
| Injections, Subcutaneous | 2 | 2005 | 34 | 0.090 |
Why?
|
| Competency-Based Education | 1 | 2008 | 9 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 1 | 2009 | 67 | 0.090 |
Why?
|
| Immunoconjugates | 2 | 1999 | 6 | 0.080 |
Why?
|
| Thrombophlebitis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 47 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2009 | 71 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2008 | 123 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2005 | 65 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2008 | 51 | 0.080 |
Why?
|
| Biological Availability | 1 | 2008 | 84 | 0.080 |
Why?
|
| Rats, Wistar | 3 | 2004 | 202 | 0.080 |
Why?
|
| Students, Pharmacy | 1 | 2008 | 37 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 336 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2008 | 212 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 145 | 0.080 |
Why?
|
| Cerebral Hemorrhage | 1 | 2008 | 103 | 0.070 |
Why?
|
| Genomics | 1 | 2008 | 201 | 0.070 |
Why?
|
| gamma-Globulins | 1 | 2006 | 5 | 0.070 |
Why?
|
| Licensure | 1 | 2006 | 5 | 0.070 |
Why?
|
| Drug and Narcotic Control | 1 | 2006 | 10 | 0.070 |
Why?
|
| Drug Industry | 1 | 2006 | 13 | 0.070 |
Why?
|
| Sulfhydryl Compounds | 2 | 2022 | 46 | 0.070 |
Why?
|
| Minerals | 2 | 2015 | 45 | 0.060 |
Why?
|
| Nutritional Requirements | 2 | 2015 | 37 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 376 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2004 | 37 | 0.060 |
Why?
|
| Food | 2 | 2015 | 95 | 0.060 |
Why?
|
| Dogs | 1 | 2004 | 138 | 0.060 |
Why?
|
| Species Specificity | 1 | 2004 | 233 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 480 | 0.060 |
Why?
|
| Rats | 4 | 2004 | 3261 | 0.060 |
Why?
|
| Bronchi | 2 | 2017 | 45 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 82 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2004 | 148 | 0.050 |
Why?
|
| Acetylcysteine | 1 | 2022 | 58 | 0.050 |
Why?
|
| Naloxone | 1 | 2021 | 50 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2021 | 50 | 0.050 |
Why?
|
| Glutathione | 1 | 2022 | 160 | 0.050 |
Why?
|
| Knowledge Bases | 1 | 2021 | 6 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 21 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2021 | 143 | 0.050 |
Why?
|
| Skin | 1 | 2002 | 173 | 0.050 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2020 | 12 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 66 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 176 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 259 | 0.040 |
Why?
|
| Organotechnetium Compounds | 1 | 1999 | 8 | 0.040 |
Why?
|
| Antioxidants | 1 | 2022 | 386 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 70 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 6 | 0.040 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2018 | 46 | 0.040 |
Why?
|
| Technetium Compounds | 1 | 1998 | 3 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2017 | 59 | 0.040 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2017 | 42 | 0.040 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 7 | 0.040 |
Why?
|
| Central America | 1 | 2016 | 9 | 0.040 |
Why?
|
| HLA-B Antigens | 1 | 2016 | 11 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 1999 | 239 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2017 | 140 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1300 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1149 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 430 | 0.030 |
Why?
|
| Avitaminosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 5 | 0.030 |
Why?
|
| Drinking Behavior | 1 | 2015 | 16 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 25 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2015 | 83 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 36 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2128 | 0.030 |
Why?
|
| Therapeutic Equivalency | 2 | 2005 | 3 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 142 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 82 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2015 | 42 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 2006 | 33 | 0.030 |
Why?
|
| Magnesium | 1 | 2015 | 95 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2005 | 102 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 818 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2017 | 366 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 124 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2005 | 269 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 1289 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 316 | 0.030 |
Why?
|
| Lipids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 4012 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 555 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 606 | 0.030 |
Why?
|
| Fermentation | 1 | 2012 | 25 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2015 | 328 | 0.030 |
Why?
|
| DNA Damage | 1 | 2015 | 341 | 0.030 |
Why?
|
| Glycolysis | 1 | 2012 | 66 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 901 | 0.030 |
Why?
|
| Child | 1 | 2019 | 2875 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 342 | 0.030 |
Why?
|
| Radioligand Assay | 2 | 2002 | 61 | 0.030 |
Why?
|
| Oxygen | 1 | 2012 | 193 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2015 | 418 | 0.020 |
Why?
|
| Genetic Privacy | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 360 | 0.020 |
Why?
|
| Thiophenes | 1 | 2010 | 31 | 0.020 |
Why?
|
| Freeze Drying | 2 | 2000 | 25 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 87 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2000 | 114 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 109 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 142 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 32 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 562 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 55 | 0.020 |
Why?
|
| Health Policy | 1 | 2010 | 149 | 0.020 |
Why?
|
| Isotope Labeling | 2 | 1999 | 27 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 454 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 5035 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 188 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 965 | 0.020 |
Why?
|
| Trachea | 1 | 2006 | 19 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2006 | 77 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 549 | 0.020 |
Why?
|
| Liposomes | 1 | 2006 | 107 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2006 | 121 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 18 | 0.020 |
Why?
|
| Back Pain | 1 | 2005 | 19 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2005 | 74 | 0.020 |
Why?
|
| Leukocytes | 1 | 2005 | 68 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 649 | 0.020 |
Why?
|
| Neutrophils | 1 | 2005 | 124 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2004 | 8 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2004 | 13 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 111 | 0.010 |
Why?
|
| Temperature | 1 | 2004 | 275 | 0.010 |
Why?
|
| Skin Absorption | 1 | 2002 | 12 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2002 | 39 | 0.010 |
Why?
|
| Diffusion | 1 | 2002 | 49 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2000 | 27 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2000 | 66 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2000 | 103 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2000 | 40 | 0.010 |
Why?
|
| Drug Stability | 1 | 1999 | 110 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 445 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 176 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1998 | 3 | 0.010 |
Why?
|
| Glucose | 1 | 1999 | 217 | 0.010 |
Why?
|